{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:57:27Z","timestamp":1792259847052,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    von Willebrand disease (VWD) is known as the most common inherited bleeding disorder. Despite this, some uncertainty remains regarding its prevalence and the distribution of different phenotypes worldwide and across ethnic groups. By leveraging genetic epidemiology approaches that enable population-scale estimates, the prevalence of VWD and its diverse phenotypes can be assessed more precisely. We estimated the global VWD prevalence and its distribution across distinct ethnic groups using the largest and most widely used publicly available genetic database. Available exome\/genome sequencing data of 807,162 (730,947 exomes, 76,215 genomes) subjects from the Genome Aggregation Database (gnomAD-v4.1) were used. Based on the allele frequencies of 321 previously reported\n                    <jats:italic>VWF<\/jats:italic>\n                    pathogenic variants identified in the gnomAD population, the estimated worldwide prevalence of VWD per 1,000 individuals was 10.6 for type 1, 1.3 for type 2A, 1.7 for type 2B, and 1.5 for type 2\u00a0M. For the recessive forms of VWD, the global prevalence was estimated to be 33.9 cases per million for type 2N and 1.3 cases per million for type 3 VWD. Once structural variants and copy number variants from gnomAD that result in loss of function were included, the estimated prevalence of type 3 slightly increased to 1.8 per million. Additionally, VWD prevalence was found to vary significantly across different ethnic groups. This updated population-based genetic prevalence indicates a substantially higher than expected frequency of VWD. Our novel finding suggests that a large number of patients remain undiagnosed.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-36145-6","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:05:38Z","timestamp":1768925138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Updated global prevalence and ethnic diversity of von Willebrand disease based on population genetics analysis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-7879","authenticated-orcid":false,"given":"Omid","family":"Seidizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Oriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"36145_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41572-024-00536-8","volume":"10","author":"O Seidizadeh","year":"2024","unstructured":"Seidizadeh, O. et al. Von Willebrand disease. Nat. Rev. Dis. Primers. 10, 51 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"36145_CR2","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"J Sadler","year":"2006","unstructured":"Sadler, J. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. R J. Thromb. Haemost. 4, 2103\u20132114 (2006).","journal-title":"R J. Thromb. Haemost"},{"key":"36145_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","volume":"5","author":"PD James","year":"2021","unstructured":"James, P. D. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 5, 280\u2013300 (2021).","journal-title":"Blood Adv."},{"key":"36145_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.jtha.2024.05.006","volume":"22","author":"O Seidizadeh","year":"2024","unstructured":"Seidizadeh, O., Baronciani, L., Lillicrap, D. & Peyvandi, F. Application of genetic testing for the diagnosis of von Willebrand disease. J. Thromb. Haemost. 22, 2115\u20132128 (2024).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","volume":"69","author":"F Rodeghiero","year":"1987","unstructured":"Rodeghiero, F., Castaman, G. & Dini, E. Epidemiological investigation of the prevalence of von willebrand\u2019s disease. Blood 69, 454\u2013459 (1987).","journal-title":"Blood"},{"key":"36145_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0022-3476(05)80384-1","volume":"123","author":"EJ Werner","year":"1993","unstructured":"Werner, E. J. et al. Prevalence of von Willebrand disease in children: a multiethnic study. J. Pediatr. 123, 893\u2013898 (1993).","journal-title":"J. Pediatr."},{"key":"36145_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","volume":"8","author":"M Bowman","year":"2010","unstructured":"Bowman, M., Hopman, W., Rapson, D., Lillicrap, D. & James, P. The prevalence of symptomatic von Willebrand disease in primary care practice. J. Thromb. Haemost. 8, 213\u2013216 (2010).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR8","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.blre.2022.101018","volume":"58","author":"FF Corrales-Medina","year":"2023","unstructured":"Corrales-Medina, F. F. et al. A need to increase von Willebrand disease awareness: vwdtest. com\u2013A global initiative to help address this gap. Blood Rev. 58, 101018 (2023).","journal-title":"Blood Rev."},{"key":"36145_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"36145_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41525-023-00375-8","volume":"16","author":"O Seidizadeh","year":"2023","unstructured":"Seidizadeh, O., Cairo, A., Baronciani, L., Valenti, L. & Peyvandi, F. Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases. NPJ Genomic Med. 16, 8:31 (2023).","journal-title":"NPJ Genomic Med."},{"key":"36145_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100 (2024).","journal-title":"Nature"},{"key":"36145_CR12","doi-asserted-by":"publisher","first-page":"102686","DOI":"10.1016\/j.rpth.2025.102686","volume":"16","author":"O Seidizadeh","year":"2025","unstructured":"Seidizadeh, O., Baronciani, L. & Peyvandi, F. Challenges and considerations of genetic testing in von Willebrand disease. Res. Pract. Thromb. Haemost. 16, 9:102686 (2025).","journal-title":"Res. Pract. Thromb. Haemost"},{"key":"36145_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/j.1538-7836.2010.03869.x","volume":"8","author":"VH Flood","year":"2010","unstructured":"Flood, V. H. et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF: CB in diagnosis of VWD. J. Thromb. Haemost. 8, 1431\u20131433 (2010).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/jth.14341","volume":"17","author":"TL Slobodianuk","year":"2019","unstructured":"Slobodianuk, T. L. et al. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding. J. Thromb. Haemost. 17, 63\u201371 (2019).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hae.14810","volume":"29","author":"JS Stonebraker","year":"2023","unstructured":"Stonebraker, J. S. et al. Reported prevalence of von Willebrand disease worldwide in relation to income classification. Haemophilia 29, 975\u2013986 (2023).","journal-title":"Haemophilia"},{"key":"36145_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10654-013-9873-0","volume":"29","author":"LC Thygesen","year":"2014","unstructured":"Thygesen, L. C. & Ersb\u00f8ll, A. K. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur. J. Epidemiol. 29, 551\u2013558 (2014).","journal-title":"Eur. J. Epidemiol."},{"key":"36145_CR17","first-page":"A12220796","volume":"27","author":"ST S\u00f8rensen","year":"2023","unstructured":"S\u00f8rensen, S. T., Kristensen, F. P., Troelsen, F. S., Schmidt, M. & S\u00f8rensen, H. T. Health registries as research tools: a review of methodological key issues. Dan. Med. J. 27, 70:A12220796 (2023).","journal-title":"Dan. Med. J."},{"key":"36145_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15386\/cjmed-1015","volume":"92","author":"B Pop","year":"2019","unstructured":"Pop, B. et al. The role of medical registries, potential applications and limitations. Med. Pharm. Rep. 92, 7\u201314 (2019).","journal-title":"Med. Pharm. Rep."},{"key":"36145_CR19","doi-asserted-by":"publisher","first-page":"102682","DOI":"10.1016\/j.rpth.2025.102682","volume":"16","author":"O Seidizadeh","year":"2025","unstructured":"Seidizadeh, O., Cairo, A., Othman, M. & Peyvandi, F. Global prevalence of platelet-type von Willebrand disease. Res. Pract. Thromb. Haemost. 16, 9:102682 (2025).","journal-title":"Res. Pract. Thromb. Haemost"},{"key":"36145_CR20","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1182\/bloodadvances.2024013421","volume":"8","author":"O Seidizadeh","year":"2024","unstructured":"Seidizadeh, O., Cairo, A., Mancini, I., George, J. N. & Peyvandi, F. Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis. Blood Adv. 8, 4386\u20134396 (2024).","journal-title":"Blood Adv."},{"key":"36145_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3324\/haematol.2012.077263","volume":"98","author":"G Castaman","year":"2013","unstructured":"Castaman, G., Goodeve, A. & Eikenboom, J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica 98, 667 (2013).","journal-title":"Haematologica"},{"key":"36145_CR22","doi-asserted-by":"crossref","unstructured":"Colonne, C. K., Reardon, B., Curnow, J. & Favaloro, E. J. Why is misdiagnosis of von Willebrand disease still prevalent and how can we overcome it? A focus on clinical considerations and recommendations. J. Blood Med. 755\u2013768 (2021).","DOI":"10.2147\/JBM.S266791"},{"key":"36145_CR23","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.rpth.2024.102567","volume":"8","author":"J Shelton","year":"2024","unstructured":"Shelton, J., Millions, M., Khalife, R. & Sun, H. L. Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study. Res. Pract. Thromb. Haemost. 8, 102567 (2024).","journal-title":"Res. Pract. Thromb. Haemost"},{"key":"36145_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/jth.15247","volume":"19","author":"O Seidizadeh","year":"2021","unstructured":"Seidizadeh, O., Peyvandi, F. & Mannucci, P. M. Von Willebrand disease type 2\u00a0N: an update. J. Thromb. Haemost. 19, 909\u2013916 (2021).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR25","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jtha.2024.06.020","volume":"22","author":"MY Daniel","year":"2024","unstructured":"Daniel, M. Y. et al. Type 2\u00a0N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs. J. Thromb. Haemost. 22, 2702\u20132712 (2024).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR26","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","volume":"125","author":"VH Flood","year":"2015","unstructured":"Flood, V. H. et al. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood 125, 2297\u20132304 (2015).","journal-title":"Blood"},{"key":"36145_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/jth.15586","volume":"20","author":"DP Maas","year":"2022","unstructured":"Maas, D. P. et al. Von Willebrand disease type 2\u00a0M: correlation between genotype and phenotype. J. Thromb. Haemost. 20, 316\u2013327 (2022).","journal-title":"J. Thromb. Haemost"},{"key":"36145_CR28","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1182\/bloodadvances.2022007216","volume":"6","author":"O Seidizadeh","year":"2022","unstructured":"Seidizadeh, O. et al. Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Adv. 6, 4031\u20134040 (2022).","journal-title":"Blood Adv."},{"key":"36145_CR29","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1182\/bloodadvances.2020003397","volume":"5","author":"L Baronciani","year":"2021","unstructured":"Baronciani, L. et al. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Adv. 5, 2987\u20133001 (2021).","journal-title":"Blood Adv."},{"key":"36145_CR30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jth.15713","volume":"20","author":"PA Christopherson","year":"2022","unstructured":"Christopherson, P. A. et al. Molecular pathogenesis and heterogeneity in type 3 VWD families in US Zimmerman program. J. Thromb. Haemost. 20, 1576\u20131588 (2022).","journal-title":"J. Thromb. Haemost"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36145-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:34:32Z","timestamp":1770802472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36145-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36145"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36145-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6577209\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.P. reports participation at educational meetings of Takeda and Spark, and the advisory board of CSL Behring, Biomarin, Roche, Sanofi, and Sobi. The other authors state that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5824"}}